Radical cell therapy trial aims to tame severe lupus
NCT ID NCT07266337
Summary
This early-stage study is testing a new cell therapy called CD19/BCMA CAR-T for adults with severe lupus that hasn't responded to standard treatments. The main goals are to find the safest and most effective dose and to see if the therapy can reduce lupus disease activity, potentially allowing patients to stop other medications. Participants will receive a one-time infusion of the modified cells and be closely monitored for safety and response over two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The General Hospital of Western Theater Command
Chengdu, Sichuan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.